Study on SKB264 and Pembrolizumab for Treating Certain Solid Tumors

Inclusion Criteria

• Must be in good general health, able to perform daily activities with minimal restrictions.
• Expected to live for at least 3 more months.
• Have one of the following conditions:
  • Recurrent or metastatic cervical cancer
  • Locally advanced or metastatic urothelial carcinoma
  • Recurrent ovarian cancer
  • Metastatic prostate cancer
• Have at least one tumor that can be measured by standard criteria.
• Able to provide a sample of the tumor for testing.
• Have good organ and bone marrow function.
• Must have recovered from any side effects of previous treatments, except those not considered risky.
• Must agree to use effective birth control during the study, following local guidelines.
• Must be able to understand and sign a consent form to participate.

Exclusion Criteria

• Have untreated or active cancer spread to the brain or spinal cord.
• Have significant heart disease.
• Have serious or uncontrolled other medical conditions.
• Have active hepatitis B or C infections.
• Have HIV that is not well controlled.
• Have active tuberculosis.
• Are allergic to Pembrolizumab, SKB264, or their ingredients.
• Have had a tissue or organ transplant from another person.
• Have been treated with TROP2 targeted therapy before.
• Have received a live vaccine within 30 days before starting the study or plan to receive one during the study.
• Are participating in another clinical trial, unless it is non-interventional or in the follow-up phase.
• Any other conditions that the study doctor believes could interfere with the study or pose a risk to the participant.